[Cooperative osteosarcoma study COSS-77: results after 4 years]

Area of Science:

• Oncology
• Pharmacology

Context:

• Osteosarcoma is a primary bone malignancy often requiring aggressive treatment.
• Neoadjuvant and adjuvant chemotherapy are standard in managing resectable osteosarcoma.

Purpose:

• To evaluate the efficacy and tolerability of a specific chemotherapy regimen in patients with resectable osteosarcoma.

Summary:

• 71 patients with resectable osteosarcoma received a one-year chemotherapy regimen comprising high-dose methotrexate, adriamycin, and cyclophosphamide.
• Adriamycin was prioritized in the initial 15 weeks, with a higher frequency of cytostatic agent administration early in treatment.
• 41 out of 71 patients remained continuously disease-free at a median follow-up of 39 months.
• Tumor lesion extension beyond one-third of the long bone length was associated with a higher relapse rate (67%) compared to smaller lesions (28%).
• One patient experienced cardiomyopathy secondary to adriamycin; overall, the therapy was well-tolerated, with 70-80% of planned dosages administered.

Impact:

• This chemotherapy protocol demonstrates potential for achieving long-term remission in resectable osteosarcoma.
• Tumor size on initial radiographic examination is a significant prognostic factor for relapse.
• Further research may refine treatment protocols based on these findings.